
## **Trustees’ Annual Report for the period** 

**From  31 Oct 2022   Period start date   To 30 Oct 2023   Period end date** 

## **Charity name: Lipodystrophy UK** 

## **Charity registration number:** 1175462 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|The objects of the CIO are:<br>i.<br>To raise awareness of Lipodystrophy<br>conditions, both within the medical<br>profession and the general public;<br>ii.<br>To provide information and support to<br>people with Lipodystrophy and those<br>affected by it;<br>iii.<br>To advocate for excellent care and<br>improved treatment options for people<br>with Lipodystrophy;<br>To encourage research addressing the<br>concerns of people with Lipodystrophy|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or<br>services identified in the<br>accounts.|Para 1.17 and<br>1.19|- Patient support activities in person and<br>online<br>- Raising awareness (World Lipodystrophy<br>Day, conferences, publications, social<br>media, focus groups)<br>- Advocacy (Part of Global Patient Leaders<br>group, Patient Journey resources,<br>Clinician discussions and relationship<br>building)|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|All trustees have had regard to the Charity<br>Commission’s guidance on public benefit.|



**Additional information (optional)** You may choose to include further statements where relevant about: 

||SORP reference||
|---|---|---|
|Policy on grant making|Para 1.38|Lipodystrophy UK does not have a policy<br>on grant making, since we don’t currently<br>offer grants|
||Para 1.38|Lipodystrophy UK does not have a policy<br>on social investment|





|Policy on social investment<br>including program related<br>investment|||
|---|---|---|
|Contribution made by<br>volunteers|Para 1.38|Lipodystrophy UK does not have a policy<br>on contributions made by volunteers|
|Other|||



## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|1) Fully funded Patient Support Day for<br>WLD 2023. An in-person, all day event<br>with a full agenda of speakers to help<br>educate, raise awareness, provide<br>information and resources and<br>opportunities for social networking. This<br>event was the highlight of the year,<br>hugely successful with fantastic<br>feedback from delegates. We funded<br>food, transport and accommodation to<br>make the event accessible for all.<br>2) Patient Journey resources being<br>developed as part of Global Patient<br>Leaders group in collaboration with<br>Amryt Pharma.<br>3) Ongoing awareness activities – World<br>Lipodystrophy Day, Rare Disease Day<br>4) Collaboration with Physicians, Pharma<br>and other Patient Group Leaders<br>(Global Patient Leaders group) on<br>development of Patient Journey<br>resources to support equality in<br>treatment.<br>5) Chair gave several awareness talks at<br>different conferences and participated in<br>focus groups with stakeholders<br>6) Ongoing individual patient support, ad<br>hoc<br>7) Ongoing relationship with National<br>Centre of Excellence in Lipodystrophy<br>(Addenbrookes Hospital)<br>8)  Ongoing patient representative on<br>ECLip Board (re-elected)<br>9)  Ongoing relationship with the Centre of<br>Appearance Research (CAR)|



## **Additional information (optional)** 

You may choose to include further statements where relevant about: 



|Achievements against<br>objectives set|Para 1.41|Ongoing objectives to 1) raise awareness<br>of Lipodystrophy conditions; 2) provide<br>information and support to people affected<br>by Lipodystrophy; advocate for excellent<br>care and improved treatment options;<br>encourage research addressing the<br>concerns of people with Lipodystrophy|
|---|---|---|
|Performance of fundraising<br>activities against objectives<br>set|Para 1.41|N/A|
|Investment performance<br>against objectives|Para 1.41|N/A|
|Other|||





## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|Low fundraising income, although sufficient<br>to cover charity expenditure|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|Lipodystrophy UK does not have a<br>reserves policy|
|Amount of reserves held|Para 1.22|N/A|
|Reasons for holding zero<br>reserves|Para 1.22|N/A|
|Details of fund materially in<br>deficit|Para 1.24|N/A|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|N/A|



|**Additional information (optional)**<br>You may choose to include further statements|**Additional information (optional)**<br>You may choose to include further statements|where relevant about:|
|---|---|---|
|The charity’s principal<br>sources of funds (including<br>any fundraising)|Para 1.47|Funds from fundraising activities and<br>expert consultancy fees|
|Investment policy and<br>objectives including any<br>social investment policy<br>adopted|Para 1.46|Lipodystrophy UK does not have an<br>investments policy|
|A description of the principal<br>risks facing the charity|Para 1.46|More fundraising activities will be needed<br>to fund more ambitious projects in the<br>future. Actively recruiting additional<br>volunteers|
|Other|||





## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:|||
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|Para 1.25|Constitution|
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25|Charitable Incorporated Organisation|
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25|Apart from the first charity trustees, every<br>trustee must be appointed by a resolution<br>passed at a properly convened meeting of<br>the charity trustees|



## **Additional information (optional)** 

You may choose to include further statements where relevant about: 

|Policies and procedures<br>adopted for the induction<br>and training of trustees|Para 1.51|N/A|
|---|---|---|
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51|N/A|
|Relationship with any related<br>parties|Para 1.51|Working in partnership with The Centre for<br>Appearance Research (CAR) as a member<br>of the Appearance Collective (AC) -<br>supporting people living with visible<br>differences.|
|Other|||



## **Reference and Administrative details** 

|Charity name|Lipodystrophy UK|
|---|---|
|Other name the charity uses|LDUK-mostly phased out|
|Registered charity number|1175462|
|Charity’s principal address|29 Collington Way,<br>Kingston Bagpuize,<br>Abingdon<br>OX13 5GP|
|||





**Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6<br>7<br>8<br>9<br>10<br>11<br>12<br>13<br>14<br>15<br>16<br>17<br>18<br>19<br>20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year **|**Name of person (or body) entitled**<br>**to appoint trustee (ifany)**|
|---|---|---|---|---|
||Rebecca Sanders|Chair|N/A|Rebecca Sanders(Founder)|
||BeckySmith|N/A|N/A|Board majorityvote|
||Siobhan Dunn|N/A|N/A|Board majorityvote|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||



## – Corporate trustees names of the directors at the date the report was approved 

**Director name** N/A 

Name of trustees holding title to property belonging to the charity 

|**Trustee name**|**Dates acted if not for whole year**||
|---|---|---|
|N/A|||
||||
||||
||||
||||
||||





## **Funds held as custodian trustees on behalf of others** 

Description of the assets N/A held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|
|---|---|---|
|**Type of**<br>**adviser**<br>**Name**<br>**Address**|||
|N/A|||
||||
||||
||||
|**Name of chief executive or names of senior staff members (Optional information)**|||
|N/A|||



## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

N/A 

## **Other optional information** 



## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

|**Signature(s)**<br>**Full name(s)**<br>**Position (eg Secretary,**<br>**Chair, etc)**<br>**Date**|||
|---|---|---|
||Rebecca Sanders||
||<br>Chair||
||04/01/2026||
||04/01/2026||






**1175462** 

**Lipodystrophy UK** 

## **Receipts and payments accounts** 

**CC16a** Period end date Oct-23 

**For the period** Period start date **To from** Oct-22 

## **Section A Receipts and payments** 

|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest**<br>**£**<br>**2 328**<br>**26 876**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**29 204**<br>**-**<br>**-**<br>**-**<br> **29 204**<br>**185**<br>**26 954**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br> **27 139**<br>**-**<br>**-**<br> **-**<br>**27 139**<br>**2 065**<br>**-**<br>**6 871**<br>**8 936**|**Restricted**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Endowment**<br>**funds**<br>**to the nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**Total funds**<br>**to the nearest £**<br>**2 328**<br>**26 876**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**29 204**<br>**-**<br>**-**<br>**-**<br>**29 204**<br>**185**<br>**26 954**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**27 139**<br>**-**<br>**-**<br>**-**<br>**27 139**<br>**2 065**|**Total funds**<br>**to the nearest £**<br>**2 328**<br>**26 876**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**29 204**<br>**-**<br>**-**<br>**-**<br>**29 204**<br>**185**<br>**26 954**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**27 139**<br>**-**<br>**-**<br>**-**<br>**27 139**<br>**2 065**|**Last year**<br>**to the nearest £**|
|---|---|---|---|---|---|---|
|Donations|**2 328**|||||**-**|
|ConsultancyFee|**26 876**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_**_(Gross income for_<br>_AR)_|**29 204**|||||**-**|
||||||||
|**A2 Asset and investment sales,**<br>**(see table).**|||||||
||**-**||||||
||**-**|||||**-**|
|**_Sub total_**|**-**|||||**-**|
|**_Total receipts_ **<br>**A3 Payments**|||||||
|||||||**-**|
||||||||
|Insurance|**185**|||||**-**|
|Invoice|**26 954**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
||**-**|||||**-**|
|**_Sub total_ **|**27 139**|||||**-**|
||||||||
|**A4 Asset and investment**<br>**purchases, (see table)**|||||||
||**-**||||||
||**-**||||||
|**_Sub total_ **|**-**|||||**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**|||||||
|||||||**-**|
||||||||
||**2 065**|**-**|**-**|**2 065**||**-**|
||**-**|**-**|**-**|**-**||**-**|
||**6 871**|**-**|**-**|**6 871**||**-**|
||**8 936**|**-**|**-**|**8 936**||**-**|



CCXX R1 accounts (SS) 

1 



## **Section B Statement of assets and liabilities at the end of the period** 

|**Categories**<br>Signed by one or two trustees on<br>behalf of all the trustees<br>**B5 Liabilities**<br>**B3 Investment assets**<br>**B2 Other monetary assets**<br>**B4 Assets retained for the**<br>**charity’s own use**<br>**B1 Cash funds**|**Details**<br>**Details**<br>**_Total cash funds_**<br>(agree balances with receipts and payments<br>account(s))<br>Bank account<br>**Details**<br>**Details**<br>**Details**<br>Signature|**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**8 936**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**8 936**<br>**-**<br>OK<br>OK<br>**Unrestricted**<br>**funds**<br>**Restricted**<br>**funds**<br>**to nearest £**<br>**to nearest £**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**asset belongs**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**Fund to which**<br>**liability relates**<br>**Amount due**<br>**(optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>Print Name<br>REBECCA SANDERS|**Endowment**<br>**funds**<br>**to nearest £**|
|---|---|---|---|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||OK|
||||**Endowment**<br>**funds**<br>**to nearest £**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**Current value**<br>**(optional)**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**-**|
||||**When due**<br>**(optional)**|
|||||
|||||
|||||
|||||
|||||
|||||
||||Date of<br>approval|
|||REBECCA SANDERS|04/01/2026|
|||||



CCXX R2 accounts (SS) 

2 



Lipodystrophy UK
a￿1￿(elle¥s %iJp[IDrt
Independent Examiner's Report
to the Tru.stees of Lipodystrophy UK
Charity number.. 1175462
Report on the accounts for the year ended Oct 2023
I report to the trustees on my examination ofthe accounts of Lipodystrophy UK for the year
ended Oct 2023.
Responsibilitie5 and basis ol report
As the charity's trustees. you are responsible for the preparation of the accounts in accordance
with the requirements of the Charities Act 2011.
I report in respect of my examination of the chariry's accounts carried out under section 145 uf
the Charities ALt 2011, and in carrying out my examinafion, I have followed the applicable
directions given by the Charity Cornmission.
Independent examiner's statement
I have examined the accounts of Llpodystrophy UK for the yearended Oct 2023, which
Lomprise a receipts and payments account and a statement of assets and Ilablllties.
My examination was carried out in accordance with the Charity Commission's guidance on
independent examination.
An examination includes a review ofthe accounting records kept by the charity and a
Lomparison of the accounts presented with those records. It also includes consideration of any
unusual items or disclosures in the accounts and seeking explanations from the trustees
concerning such matters.
Independent examiner's conclusion
On the basis of my examination, I have not become aware of any matter which gives me
reasonable cause to believe that in any mdtL'rial respect:
The accounting records woro not kept in accordance with section 130 of the Charities
Act 2011,. or
The accounts do nnt accord with the accounting records. or
The accounts do not comply with the applicable requirements of the Charities Act 2011.
I have no matters to report in relation to those matters set out in section 145(5) ofthe
Charities Act 2011.
Name: lullane Ober-Blobaum
Signature:
Date:
i('lJ dL,
Independent Examinerfs address:
4 Hazel Gardens
OXII 6DF Didcot
Oxtordshire, UK
www.lipodystrophyulLorg
Lipodystrophy UK
Registered Charity- 1175462